# Managed Access Programs for BYL719, Alpelisib

> **NCT04085653** · — · AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- PIK3CA-Related Overgrowth Spectrum (PROS)
- Breast Cancer

## Interventions

- **DRUG:** alpelisib

## Key facts

- **NCT ID:** NCT04085653
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04085653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04085653, "Managed Access Programs for BYL719, Alpelisib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04085653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*